CMPX

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, headquartered in Boston, Massachusetts. Founded in 2014, the company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead drug candidates include tovecimig (CTX-009), a bispecific antibody targeting DLL4 and VEGF-A in Phase 2/3 trials for biliary tract cancer; CTX-8371, a next-generation bispecific checkpoint inhibitor targeting PD-1 and PD-L1 with demonstrated responses in both solid tumor and hematologic malignancies; CTX-10726, a tetravalent PD-1 x VEGF-A bispecific antibody; and CTX-471, an anti-CD137 agonist antibody. The company had an estimated $127 million in cash and marketable securities as of December 31, 2024, providing cash runway into Q1 2027.